Immucell (ICCC) Research & Development (2010 - 2026)

Immucell (ICCC) has reported Research & Development for 17 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 33.52% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (up 17.64% YoY), and the FY2025 full-year result was $3.6 million, down 8.85% from the prior year.
• Research & Development rose to $1.1 million in Q2 2026 per ICCC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Research & Development topped out at $1.3 million in Q3 2022 and bottomed at $819393.0 in Q4 2024.
• Historically, Research & Development has averaged $1.0 million across 5 years, with a median of $1.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Research & Development sank 32.15% in 2025, then jumped 33.52% in 2026.
• Over 5 years, Research & Development stood at $1.0 million in 2022, then climbed by 6.58% to $1.1 million in 2023, then slipped by 26.74% to $819393.0 in 2024, then jumped by 31.97% to $1.1 million in 2025, then grew by 2.72% to $1.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.1 million, $1.1 million, and $919291.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.